Triptolide, an active component extracted from the medicinal plant Tripterygium wilfordii Hook F., has been used to treat various diseases, including lupus, cancer, rheumatoid arthritis and nephritic syndrome. The present study investigated the effects of triptolide on multiple myeloma using western blotting and an electrophoretic mobility shift assay. Triptolide was found to suppress the inducible and constitutive activation of signal transducer and activator of transcription 3 (STAT3), which is closely associated with inflammation and tumorigenesis. Triptolide also inhibited the DNA binding of STAT3. This correlated with the downregulation of Src kinase and Janus kinase 1 and 2, and with the upregulation of protein tyrosine phosphatase non-receptor type 6 (also known as SHP-1). In addition, trip-tolide downregulated the expression of the STAT3-regulated antiapoptotic (Bcl-xL and myeloid cell leukemia-1), proliferative (cyclin D1), and angiogenic (vascular endothelial growth factor) genes, suggesting that triptolide can induce apoptosis of tumor cells. These results suggest that triptolide may be a potential therapeutic anticancer agent for the prevention and treatment of multiple myeloma; thus further in-depth investigations into its efficacy and toxicity are warranted.
triptolidemultiple myelomasignal transducer and activator of transcription 3Janus kinaseSHP-1Introduction
Multiple myeloma (MM), also known as plasma cell myeloma, myelomatosis or Kahler's disease (1), is a cancer of plasma cells (the white blood cells that produce antibodies), and is considered to be incurable (2). The incidence of MM is ~4/100,000 and it accounts for 10% of all hematological malignancies (3). The treatment of MM is complex due to rapid advances in stem cell transplantation, medications and supportive care, which have improved the survival times of MM patients over the past 30 years (4). The principal treatments include stem cell (bone marrow) transplantation, non-chemotherapeutic drugs that target cancer cells, standard chemotherapeutic drugs, and corticosteroids (5). However, despite various treatment options for MM, advanced combination therapies with effective agents are required for the efficient treatment of the disease in the first-line and relapsed settings, and this has resulted in the development of novel agents (6,7).
Traditional Chinese medicine (TCM) is considered to be an important source of therapies for various diseases. In 2015, a Chinese scientist won the Nobel Prize for her work in drug development from TCM; indeed, numerous drug candidate compounds from TCM are under investigation (8). Triptolide is a diterpenoid epoxide that can be isolated from the traditional Chinese medicinal herb Tripterygium wilfordii Hook F., which is used to treat inflammatory and autoimmune diseases (9). Following the initial identification of triptolide in 1972, in vivo and in vitro experiments have revealed it to exhibit a variety of bioactivities, including immunosuppression and antiinflammatory effects (10,11). Triptolide has a complex mechanism of action, which involves inhibition of transcription factor nuclear factor κB (NF-κB) activation (12,13), suppression of the production of prostaglandin E2, and reduction of cytokine levels (13,14).
In addition to the aforementioned activities, it was recently reported that triptolide has antitumor effects in pancreatic, gastric, breast, adrenal and thyroid cancer, as well as neuroblastoma (1,15–19). Likewise, a number of studies on the effects of triptolide on various types of cancer cells, including MM, are currently underway. Although there have been numerous attempts to explain the molecular mechanisms underlying the effect of triptolide, the mechanism in MM cells remains unclear. It has been proposed that triptolide induces epigenetic alterations via the regulation of histone methylation (20), and induces apoptosis via the activation of caspases-8, -9 and -3 (cysteine proteases) in MM cells (21). However, a greater understanding of its mechanism of action in MM cells is necessary in order to develop novel anticancer drugs from triptolide, due to its potential multi-organ toxicity and narrow therapeutic window.
Notably, triptolide inhibits the Janus kinase (JAK)2 pathway in myeloproliferative disorder cells, which is a similar disease to MM (22), and it inhibits the JAK1/signal transducer and activator of transcription 3 (STAT3) and JAK2/STAT3 pathways in colon cancer cells and in a rat neuropathic pain model, respectively (23,24). STATs consist of a family of six transcription factors that regulate tumor development (25). Ligand-induced activation of cell-surface cytokine receptors activates the JAK family, which phosphorylates and activates latent cytoplasmic STAT3 protein to form an active dimer (26). Activated STAT3 translocates to the nucleus and induces transcription of STAT3-regulated genes (26). Several cytokines, including IL-6 (27), transforming growth factor-α (28) and epidermal growth factor (EGF) (27) have been shown to activate STAT3. Numerous studies have proposed that the activation of STAT3 can suppress apoptosis, and promote proliferation, angiogenesis, chemoresistance and inflammation (29–32). Thus, the STAT3 pathway must be considered to gain an understanding of oncogenesis (25). Therefore, in the present study, the effect of triptolide on MM cells via the JAK and JAK2/STAT3 pathways was investigated.
The present study aimed to investigate the effects of triptolide on the STAT3 activation pathway and the underlying mechanism in MM cells. The structure of triptolide is shown in Fig. 1. The effect of triptolide on constitutive and IL-6-induced STAT3 activation was evaluated. The effect of triptolide on STAT3-mediated gene products associated with cellular proliferation, survival and apoptosis was also investigated. Triptolide was found to suppress STAT3 activation by activating protein tyrosine phosphatase non-receptor type 6 (SHP-1), and down-regulated the expression of STAT3-regulated antiapoptotic, proliferative and angiogenic proteins.
Materials and methodsMaterials
A 50-mM solution of triptolide with purity >95% was kindly provided by Dr Aggarwal at MD Anderson Cancer Center (Houston, TX, USA). Hoechst 33342, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Tris, glycine, NaCl, SDS, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). RPMI-1640 medium, fetal bovine serum (FBS), 0.4% trypan blue vital stain, and antibiotic/antimycotic mixture were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The rabbit polyclonal anti-STAT3 antibody (#sc-482) and mouse monoclonal antibodies against phospho (p)-STAT3 (Tyr-705; #sc-8059), Bcl-xL (#sc-8392), SHP-1 (#sc-7289), cyclin D1 (#sc-753), procas-pase-3 (#sc-373730), JAK2 (#sc-278), VEGF (#sc-53462), Mcl-1 (#sc-53951) and poly(ADP-ribose) polymerase (PARP; #sc-7150) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (#1662408) was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA). Antibodies against phospho-specific Src (Tyr-416; #2101S), Src (#2108), phospho-specific JAK1 (Tyr-1022/1023; #3331S), p-JAK2 (#3771S), and JAK1 (#3332) were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). The HRP-conjugated goat anti-mouse antibody (#554002) was purchased from Transduction Laboratories (Lexington, KY, USA). Bacteria-derived recombinant human IL-6 was obtained from Novartis Pharmaceuticals (East Hanover, NJ, USA).
Cell lines
The human MM cell lines U266 and dexamethasone-sensitive MM.1S were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cell lines were cultured in RPMI-1640 medium containing 10% FBS and 1X antibiotic/antimycotic solution. Cells were maintained at 37°C in an atmosphere of 5% CO2, 95% air.
Western blot analysis
For the detection of p-STAT3 (Tyr-705) and STAT3 proteins, triptolide-treated whole-cell extracts were lysed in lysis buffer [20 mM Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.4 mM phenylmethylsulfonyl fluoride, and 4 mM Na3VO4]. Lysates were then centrifuged at 16,025 × g for 10 min to remove insoluble material. The extracted proteins were resolved on a 7.5% SDS polyacrylamide gel. Following electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane, blocked with 5% non-fat milk, and probed with anti-p-STAT3 antibodies (1:500) and anti-STAT3 antibodies (1:1,000) overnight at 4°C. The blot was then washed, exposed to HRP-conjugated secondary antibodies (1:10,000) at room temperature for 1 h, and finally examined by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA).
To detect the expression of STAT3-regulated proteins and caspase-3, U266 cells (2×106/ml) were treated with 60 μM triptolide for the indicated times. The cells were then washed and proteins were extracted by incubation for 30 min on ice in 0.05 ml of buffer containing 20 mM HEPES (pH 7.4), 2 mM EDTA, 250 mM NaCl, 0.1% Nonidet P-40, 2 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.5 μg/ml benzamidine, 1 mM DTT, and 1 mM sodium orthovanadate. The lysate was centrifuged, and the supernatant was collected. Whole-cell protein extract (50 μg) was resolved by 10% SDS-PAGE; electrotransferred onto a nitrocellulose membrane; blotted with antibodies against Bcl-xL (1:500), myeloid cell leukemia-1 (Mcl-1; 1:500), cyclin D1 (1:1,000), VEGF (1:1,000), and caspase-3 (1:1,000) overnight at 4°C. The blots were washed, exposed to HRP-conjugated goat anti-mouse antibodies for 1 h at room temperature, and then detected by enhanced chemiluminescence.
Electrophoretic mobility shift assay (EMSA)
DNA binding of STAT3 was analyzed by EMSA using a 32P-labeled high-affinity sis-inducible element probe, as previously described (33). Briefly, nuclear extracts were prepared from γ-T3-treated cells and incubated with high-affinity sis-inducible element probes (5′-CTTCATTTCCCGTAAATCCCTAAAGCT-3′ and 5′-AGCTTTAGGGATTTACGGGAAATGA-3′). The DNA-protein complexes that formed were separated from free oligonucleotides on 5% native polyacrylamide gels. The dried gels were visualized, and the radioactive bands were quantitated with a Storm 820 Phosphorimager and ImageQuant TL 7.0 (both from Amersham; GE Healthcare Life Sciences, Little Chalfont, UK).
Western blot analysis of PARP degradation
Triptolide-induced apoptosis was examined by proteolytic cleavage of PARP. Briefly, cells (2×106/ml) were treated with 60 μM triptolide for the indicated times at 37°C. The cells were then washed and subjected to protein extraction by incubation for 30 min on ice in 0.05 ml buffer containing 20 mM HEPES (pH 7.4), 2 mM EDTA, 250 mM NaCl, 0.1% Nonidet P-40, 2 ng/ml leupeptin, 2 ng/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.5 ng/ml benzamidine, 1 mM DTT, and 1 mM sodium orthovanadate. The lysate was centrifuged, and the supernatant was collected. Protein extract (40 μg) was resolved by 10% SDS-PAGE, electrotransferred onto a nitrocellulose membrane, blotted with anti-PARP antibody, overnight at 4°C. The blot was washed, exposed to HRP-conjugated goat anti-mouse antibody for 1 h at room temperature, and then detected by enhanced chemiluminescence.
ResultsTriptolide downregulates constitutive STAT3 activation in a dose- and time-dependent manner
Whether triptolide regulates constitutive STAT3 activation in MM cells was examined by determination of STAT3 phosphorylation. Whole-cell extracts were prepared from U266 cells pretreated for 6 h with various concentrations of triptolide and STAT3 phosphorylation was examined by western blot analysis using an anti-p-STAT3 (Tyr705) antibody. Triptolide inhibited the constitutive activation of STAT3 in U266 cells, with maximum inhibition at 100 nM (Fig. 2A). Under these conditions, triptolide had no effect on the STAT3 protein level (Fig. 2A). The incubation time required for suppression of STAT3 activation by triptolide was also examined in U266 cells. Triptolide inhibited the activation of STAT3 in a time-dependent manner, with maximum inhibition occurring at 24 h, again with no effect on the STAT3 protein level (Fig. 2B).
Triptolide inhibits DNA binding of STAT3
It was investigated whether triptolide reduces the DNA-binding activity of STAT3 based on the fact that phosphorylation of STAT3 regulates gene transcription via its dimerization, nuclear translocation and DNA binding. An EMSA using nuclear extracts of U266 cells was performed; the results indicated that triptolide decreased the DNA-binding activity of STAT3 in a dose-dependent (Fig. 2C) and time-dependent (Fig. 2D) manner. Thus, triptolide is capable of eliminating the DNA-binding ability of STAT3.
Triptolide suppresses constitutive activation of Src, JAK1, and JAK2
STAT3 may be constitutively activated by soluble tyrosine kinases of the Src kinase (34) and JAK (35) families. Therefore, the effects of triptolide on the constitutive activation of Src kinase, JAK1 and JAK2 in U266 cells were investigated. Triptolide was found to suppress the constitutive phosphorylation of JAK1 (Fig. 3A) and JAK2 (Fig. 3B) in a dose-dependent manner, while the total levels of JAK1 and JAK2 remained unchanged under the same conditions (Fig. 3A and B). As shown in Fig. 3C, triptolide suppressed the constitutive phosphorylation of Src kinase in a dose-dependent manner, while the total Src kinase protein levels remained unchanged (Fig. 3C).
Triptolide inhibits inducible STAT3 phosphorylation in MM cells
Because STAT3 is also activated by phosphorylation at tyrosine residues in response to IL-6 (27), it was investigated whether triptolide could inhibit IL-6-induced STAT3 phosphor-ylation in MM.1S cells, which lack constitutively active STAT3. As shown in Fig. 4A, IL-6 induced phosphorylation of STAT3 in a dose-dependent manner. IL-6-induced STAT3 phosphorylation was suppressed by triptolide in a dose-dependent manner (Fig. 4B). A triptolide concentration >50 nM was sufficient to suppress IL-6-induced STAT3 phosphorylation.
Triptolide induces the expression of SHP-1
SHP-1, a non-receptor-type protein tyrosine phosphatase, is known to negatively regulate the STAT3 signaling pathway (36,37). Therefore, it was examined whether the inhibition of STAT3 phosphorylation by triptolide was due to the increased expression of SHP-1. As shown in Fig. 5A, triptolide upregulated SHP-1 expression in a time-dependent manner.
Triptolide downregulates the expression of genes associated with cell survival, proliferation, and angiogenesis
The expression of the antiapoptotic proteins Mcl-1 and Bcl-xL, the cell cycle regulator protein cyclin D1, and the angiogenic protein VEGF, all of which have been reported to be regulated by STAT3 (25,38), were downregulated by triptolide treatment (Fig. 5B). Tript olide downregulated the expression of these proteins in a time-dependent manner, with maximum suppression at 24 h after the beginning of treatment (Fig. 5B).
Triptolide causes caspase-3 activation and PARP cleavage
As caspase-3 is critically involved in the regulation of antiapoptotic proteins (39) and VEGF (40), it was determined whether triptolide could activate caspase-3. Treatment of U266 cells with 100 nM triptolide induced caspase-3-dependent cleavage of a 118-kDa PARP protein into an 87-kDa fragment in a time-dependent manner (Fig. 5C).
Discussion
The Chinese herb T. wilfordii has been used for centuries as a traditional medicine for treating fever, chills and edema. Triptolide, a component extracted from T. wilfordii, has been intensively researched in recent years as it exhibits potent antitumor activity in various cancerous cells, such as human promyelocytic leukemia, T cell lymphoma, human hepatocellular carcinoma, cervical adenocarcinoma, pancreatic carcinoma, oral cancer cell and cholangiocarcinoma (41–43). However, triptolide has a serious drawback as an antitumor agent: Its toxicity (44). For this reason, the mechanism of action of triptolide in cancerous cells must be determined, as this would allow its toxicity to be reduced through chemical modification.
STAT3 is an important signaling pathway that has been associated with inflammation, survival, proliferation, chemoresistance, and angiogenesis (26). The results of the present study indicated that triptolide suppressed the phosphorylation of JAK1 and JAK2, which are upstream regulators of STAT3. Two STAT3 activation pathways were considered: i) IL-6-induced STAT3 activation via the IL-6/JAK/STAT3 cell signaling pathway, in which IL-6 binding to its receptor leads to phosphorylation of JAK, and phosphorylated JAK sequentially induces STAT3 phosphorylation; and ii) constitutive STAT3 activation involving various protein kinases (26,45,46). The IL-6/JAK/STAT3 signaling pathway serves a critical role in the growth, invasion and metastasis of cancerous cells (47). Constitutively active STAT3 is also important in the survival and proliferation of myeloma, as ~48% of MM patients have a constitutively active form of STAT3 (48). Regarding the mechanisms of STAT3 inhibition, it was observed in the present study that triptolide inhibited IL-6-induced and constitutive STAT3 activation in MM cells. It was also demonstrated that the mechanism of action of triptolide involves inhibition of induction of SHP-1, as well as activation of JAK1, JAK2 and c-Src. This is closely associated with the inhibition of the expression of various STAT3-regulated proteins and the induction of apoptosis in MM cells.
SHP-1, a negative regulator of the JAK/STAT signaling pathway, is hypermethylated in 79% of MM patients (46), and demethylation of SHP-1 decreases STAT3 activation (49). In the present study, it was demonstrated that triptolide could induce SHP-1 expression, suggesting that the induction of SHP-1 may have inhibited STAT3 activation. Abnormal methylation of suppressor of cytokine signaling 1, another regulator of the JAK/STAT3 signaling pathway, has also been observed in MM patients (50). However, this was not considered in the present study, as methylation of this gene is not strongly correlated with the clinical outcome of MM patients (50).
The present study also demonstrated that triptolide can suppress the activation of Src. Phosphorylation of Src serves a critical role in tumor cell survival. The majority of Src-transformed cell lines have persistently activated STAT3 and dominant-negative STAT3 blocks transformation (51). Furthermore, constitutive STAT3 activation has been implicated in the increased resistance to apoptosis, which leads to radiation resistance and chemoresistance (51). This may be mediated by the expression of the STAT3-regulated gene products including Bcl-xL, Mcl-1, and cyclin D1. Antiapoptotic proteins such as Bcl-xL and Mcl-1 inhibit the induction of cell death by various chemotherapeutic drugs, in parallel with an increase in chemoresistance (52). The present study demonstrated that triptolide downregulated Bcl-xL, Mcl-1 and cyclin D1, which implies that the suppression of STAT3 activation by triptolide may facilitate the apoptosis of MM cells. It was also found that triptolide downregulated the expression of VEGF, which is involved in angiogenesis of cancer cells, suggesting that triptolide may exert an antiangiogenic effect by downregulating VEGF.
Triptolide was previously reported to inhibit the transcription factor, NF-κB (21). However, it is unclear whether the inhibition of NF-κB activation is linked to the inhibition of STAT3 activation by triptolide. NF-κB and STAT3 are activated by different cytokines; for example, tumor necrosis factor is a major activator of NF-κB, whereas IL-6 activates STAT3. However, notably, JAK activation has been reported to regulate both STAT3 and NF-κB activation (53). Therefore, triptolide is a potent chemotherapeutic agent targeting JAK regulation, which regulates NF-κB and STAT3 activation.
Triptolide has been widely used in East Asia for centuries for the treatment of inflammatory and autoimmune diseases, and the antitumor activity of triptolide has been investigated in various cancer cell types. The present study demonstrated that triptolide inhibits both inducible and constitutive STAT3 activation in MM cells, suggesting that it suppresses tumor cell survival, proliferation and angiogenesis. Although several barriers to the clinical use of triptolide remain to be overcome, further development of triptolide derivatives and clinical studies may result in the development of novel anticancer agents.
Acknowledgments
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (grant no. NRF-2016R1A6A1A03011325)
AbbreviationsSTAT3
signal transducer and activator of transcription 3
JAK
Janus kinase
SHP-1
protein tyrosine phosphatase non-receptor type 6
Mcl-1
myeloid cell leukemia-1
VEGF
vascular endothelial growth factor
IL-6
interleukin-6
PARP
poly(ADP-ribose) polymerase
MM
multiple myeloma
ReferencesYangSChenJGuoZXuXMWangLPeiXFYangJUnderhillCBZhangLTriptolide inhibits the growth and metastasis of solid tumorsMol Cancer Ther26572200312533674RaabMSPodarKBreitkreutzIRichardsonPGAndersonKCMultiple myelomaLancet374324339200910.1016/S0140-6736(09)60221-X19541364JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin60277300201010.3322/caac.2007320610543KumarSKDispenzieriALacyMQGertzMABuadiFKPandeySKapoorPDingliDHaymanSRLeungNContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia2811221128201410.1038/leu.2013.3134000285KyleRARajkumarSVTreatment of multiple myeloma: a comprehensive reviewClin Lymphoma Myeloma9278288200910.3816/CLM.2009.n.056197173773910142KyleRATargeted therapy of multiple myelomaHematology17Suppl 11251282012AndersonKCThe 39th David A. Karnofsky Lecture: bench-to- bedside translation of targeted therapies in multiple myelomaJ Clin Oncol30445452201210.1200/JCO.2011.37.8919222157544800820KongLYTanRXArtemisinin, a miracle of traditional Chinese medicineNat Prod Rep3216171621201510.1039/C5NP00133A26561737DingGSImportant Chinese herbal remediesClin Ther934535719873607815ChenBJTriptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook FLeuk Lymphoma42253265200110.3109/1042819010906458211699390WuRLiYGuoZGongJZhuWLiNLiJTriptolide ameliorates ileocolonic anastomosis inflammation in IL-10 deficient mice by mechanism involving suppression of miR-155/SHIP-1 signaling pathwayMol Immunol56340346201310.1016/j.molimm.2013.05.00623911388WeiXGongJZhuJWangPLiNZhuWLiJThe suppressive effect of triptolide on chronic colitis and TNF-alpha/TNFR2 signal pathway in interleukin-10 deficient miceClin Immunol129211218200810.1016/j.clim.2008.07.01818757245QiuDKaoPNImmunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. fDrugs R D4118200310.2165/00126839-200304010-0000112568630LinNLiuCXiaoCJiaHImadaKWuHItoATriptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis miceBiochem Pharmacol73136146200710.1016/j.bcp.2006.08.027ZhuWHeSLiYQiuPShuMOuYZhouYLengTXieJZhengXAnti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cellsVascul Pharmacol524654201010.1016/j.vph.2009.10.006BanerjeeSSangwanVMcGinnOChughRDudejaVVickersSMSalujaAKTriptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1J Biol Chem2883392733938201310.1074/jbc.M113.500983241295633837133PhillipsPADudejaVMcCarrollJABorja-CachoDDawraRKGrizzleWEVickersSMSalujaAKTriptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70Cancer Res6794079416200710.1158/0008-5472.CAN-07-107717909050WuPPLiuKCHuangWWMaCYLinHYangJSChungJGTriptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathwayOncol Rep255515572011ZhengYZhangWJWangXMTriptolide with potential medicinal value for diseases of the central nervous systemCNS Neurosci Ther197682201310.1111/cns.12039ZhaoFChenYLiRLiuYWenLZhangCTriptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitroToxicology2677079201010.1016/j.tox.2009.10.023YinjunLJieJYunguiWTriptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cellsLeuk Res2999105200510.1016/j.leukres.2004.05.014ChenQLuZJinYWuYPanJTriptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1Cancer Lett291246255201010.1016/j.canlet.2009.10.019TangJLiZHGeSNWangWMeiXPWangWZhangTXuLXLiJLThe inhibition of spinal astrocytic JAK2-STAT3 pathway activation correlates with the analgesic effects of triptolide in the rat neuropathic pain modelEvid Based Complement Alternat Med2012185167201210.1155/2012/185167WangZJinHXuRMeiQFanDTriptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progressionExp Mol Med41717727200910.3858/emm.2009.41.10.078195614012772974AggarwalBBSethiGAhnKSSandurSKPandeyMKKunnumakkaraABSungBIchikawaHTargeting signal -transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solutionAnn N Y Acad Sci1091151169200610.1196/annals.1378.063YuHKortylewskiMPardollDCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNat Rev Immunol74151200710.1038/nri1995ZhongZWenZDarnellJEJrStat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6Science2649598199410.1126/science.81404228140422GrandisJRDrenningSDChakrabortyAZhouMYZengQPittASTweardyDJRequirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitroJ Clin Invest10213851392199810.1172/JCI37859769331508986ZushiSShinomuraYKiyoharaTMiyazakiYKondoSSugimachiMHigashimotoYKanayamaSMatsuzawaYSTAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cellsInt J Cancer78326330199810.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-49766567ShenYDevganGDarnellJEJrBrombergJFConsti tutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1Proc Natl Acad Sci USA9815431548200110.1073/pnas.98.4.1543BhattacharyaSRayRMJohnsonLRSTAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cellsBiochem J392335344200510.1042/BJ20050465160484381316269AokiYFeldmanGMTosatoGInhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphomaBlood10115351542200310.1182/blood-2002-07-2130YuCLMeyerDJCampbellGSLarnerACCarter-SuCSchwartzJJoveREnhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoproteinScience2698183199510.1126/science.75415557541555SchreinerSJSchiavoneAPSmithgallTEActivation of STAT3 by the Src family kinase Hck requires a functional SH3 domainJ Biol Chem2774568045687200210.1074/jbc.M20425520012244095IhleJNSTATs: signal transducers and activators of transcriptionCell84331334199610.1016/S0092-8674(00)81277-58608586ChimCSFungTKCheungWCLiangRKwongYLSOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathwayBlood10346304635200410.1182/blood-2003-06-200714976049OkaTOuchidaMKoyamaMOgamaYTakadaSNakataniYTanakaTYoshinoTHayashiKOharaNGene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomasCancer Res6263906394200212438221YuHJoveRThe STATs of cancer - new molecular targets come of ageNat Rev Cancer497105200410.1038/nrc127514964307WeinmannPGaehtgensPWalzogBBcl-Xl- and Bax-alpha-mediated regulation of apoptosis of human neutrophils via caspase-3Blood9331063115199910216108JinKMaoXOBatteurSPMcEachronELeahyAGreenbergDACaspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factorNeuroscience108351358200110.1016/S0306-4522(01)00154-311734367ChanEWChengSCSinFWXieYTriptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell linesToxicol Lett1228187200110.1016/S0378-4274(01)00353-811397559ChenYWLinGJChiaWTLinCKChuangYPSytwuHKTriptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivoOral Oncol45562568200910.1016/j.oraloncology.2008.10.00719359213TengchaisriTChawengkirttikulRRachaphaewNReutrakulVSangsuwanRSirisinhaSAntitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamstersCancer Lett133169175199810.1016/S0304-3835(98)00222-5PyattDWYangYMehosBLeAStillmanWIronsRDHematotoxicity of the chinese herbal medicine Tripterygium wilfordii Hook f in CD34-positive human bone marrow cellsMol Pharmacol57512518200010692491SchindlerCDarnellJEJrTranscriptional responses to polypeptide ligands: the JAK-STAT pathwayAnnu Rev Biochem64621651199510.1146/annurev.bi.64.070195.0032017574495HodgeDRHurtEMFarrarWLThe role of IL-6 and STAT3 in inflammation and cancerEur J Cancer4125022512200510.1016/j.ejca.2005.08.01616199153ChangQBournazouESansonePBerishajMGaoSPDalyLWelsJTheilenTGranittoSZhangXThe IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasisNeoplasia15848862201310.1593/neo.13706238144963689247Quintanilla-MartinezLKremerMSpechtKCalzada-WackJNathrathMSchaichRHöflerHFendFAnalysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive eventsAm J Pathol16214491461200310.1016/S0002-9440(10)64278-2127070281851203ZhangQRaghunathPNVonderheidEOdumNWasikMALack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoterAm J Pathol15711371146200010.1016/S0002-9440(10)64629-9110218181850163DepilSSaudemontAQuesnelBSOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myelomaLeukemia1716781679200310.1038/sj.leu.240301212886263Catlett-FalconeRLandowskiTHOshiroMMTurksonJLevitzkiASavinoRCilibertoGMoscinskiLFernández-LunaJLNuñezGConstitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cellsImmunity10105115199910.1016/S1074-7613(00)80011-410023775Heere-RessEThallingerCLucasTSchlagbauer-WadlHWacheckVMoniaBPWolffKPehambergerHJansenBBcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapyInt J Cancer992934200210.1002/ijc.1024811948488DigicayliogluMLiptonSAErythropoietin-mediated neuro-protection involves cross-talk between Jak2 and NF-kappaB signalling cascadesNature412641647200110.1038/3508807411493922
Chemical structure of triptolide (molecular weight, 360.4)
Triptolide inhibits constitutively active STAT3 in U266 cells. (A) Triptolide suppresses p-STAT3 levels in a dose-dependent manner. U266 cells (2×106/ml) were treated with the indicated concentrations of triptolide for 24 h, after which whole-cell extracts were prepared, and 30 μg of protein was resolved on 7.5% SDS-PAGE gel, electrotransferred onto nitrocellulose membranes and probed for p-STAT3. (B) Triptolide suppresses p-STAT3 levels in a time-dependent manner. U266 cells (2×106/ml) were treated with 100 nM triptolide for the indicated durations and analyzed for p-STAT3 levels. (C) Triptolide suppresses STAT3 DNA binding in a dose-dependent manner. U266 cells (2×106/ml) were treated with the indicated concentrations of triptolide for 24 h and analyzed for nuclear STAT3 levels by EMSA. (D) U266 cells (2×106/ml) were treated with 100 nM triptolide for the indicated durations and analyzed for nuclear STAT3 levels by EMSA. STAT3, signal transducer and activator of transcription 3; p-, phospho-; EMSA, electrophoretic mobility shift assay.
Triptolide downregulates constitutively active JAK1, JAK2 and Src. Triptolide downregulates (A) p-JAK1 expression, (B) p-JAK2 expression, and (C) p-Src levels in a dose-dependent manner. In all experiments, U266 cells (2×106/ml) were treated with the indicated doses of triptolide for 24 h, after which whole-cell extracts were prepared, and 40 μg of those extracts were resolved by SDS-PAGE, electrotransferred onto nitrocellulose membranes, and probed with p-JAK1, p-JAK2 and p-Src, respectively. JAK, Janus kinase; p-, phospho-.
Triptolide downregulates IL-6-induced p-STAT3. (A) IL-6 induces p-STAT3 levels in a dose-dependent manner. MM.1S cells (2×106/ml) were treated with the indicated doses of IL-6 for 30 min. (B) Triptolide down-regulates IL-6-induced p-STAT3 levels in a dose-dependent manner. MM.1S cells (2×106/ml) were treated with the indicated doses of triptolide for 24 h and then stimulated with IL-6 (10 ng/ml) for 30 min. Whole cells were then prepared and analyzed for p-STAT3 by western blotting. IL-6, interleukin 6; p-, phospho-; STAT3, signal transducer and activator of transcription 3.
Triptolide upregulates SHP-1 and downregulates STAT3-regulated antiapoptotic proteins. (A) Triptolide induces the expression of SHP-1 protein in U266 cells. U266 cells (2X106/ml) were treated with triptolide (100 nM) for the indicated times. Whole-cell extracts were prepared, and 40 μg of those extracts were resolved by 10% SDS-PAGE, electrotransferred onto nitrocellulose membranes, and probed with anti-SHP-1 antibody. (B) Triptolide suppresses STAT3-regulated gene products. U266 cells (2×106/ml) were treated with 100 nM triptolide for the indicated time intervals. Whole cell extracts were prepared, 40 μg of those extracts were resolved by 10% SDS-PAGE and probed against Mcl-1, cyclin D1, VEGF and Bcl-xL antibodies. (C) Triptolide induces caspase-3-dependent PARP cleavage. U266 cells were treated with 100 nM triptolide for the indicated times, and whole cell extracts were prepared, separated by SDS-PAGE and subjected to western blot analysis with anti-caspase-3 and anti-PARP antibodies. In all experiments, the same blots were stripped and reprobed with anti-β-actin antibody to verify equal protein loading. SHP-1, protein tyrosine phosphatase non-receptor type 6; STAT3, signal transducer and activator of transcription 3; Mcl-1, myeloid cell leukemia-1; VEGF, vascular endothelial growth factor; PARP, poly(ADP-ribose) polymerase.